Can I get it?
Yes, if a doctor decides it is right for you. Caverject is authorised in the EU and can be prescribed after a medical review.
Caverject · BadajozPrescription only
Online medical consultation for Caverject in Badajoz.
An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription valid in any pharmacy in Spain. Consultation €35, refunded if the doctor decides it is not safe to prescribe.
- A non-PDE5 route
- Direct, local action
- An option when oral PDE5s don't work or aren't allowed
Start consultationStart consultation · €35
Full refund if a review is not approved · Medication, if prescribed, is dispensed and paid for separately at a pharmacy.
IN PLAIN TERMS
What Caverject is, and how to get treatment
Alprostadil is a copy of prostaglandin E1, a substance the body makes naturally that widens blood vessels. Unlike the tablets, it is applied straight to the penis - as a cream on the tip, as an injection into the side of the shaft, or as a small pellet placed into the urethra - so it acts on the blood vessels directly. It has been authorised in EU countries for erectile dysfunction since 1994 as an injection and since 2014 as a cream. Because it works locally, the main side effects are also local: burning, pain or redness where it is applied, and rarely an erection that lasts too long, which needs urgent medical attention.
Caverject has been authorised for use in the EU since 29 November 1994, so a licensed doctor can prescribe it when it is clinically appropriate for you.
What can I take instead?
Our doctors review every Sexual health option and recommend what fits your history and goals.
See all Sexual health optionsWhat do the studies show?
Every trial behind Caverject is listed below with how many people took part and whether the results are peer-reviewed or a company announcement.
Jump to the studiesLocal consultation facts
Can I get Caverject in Badajoz?
Yes. People in Badajoz, Spain, can request an online doctor consultation about Caverject with Hi-Doctor. A licensed EU doctor reviews the case and issues a prescription only when clinically appropriate. If approved, the electronic prescription arrives as a QR code that can be dispensed directly in Spain.
Availability
Caverject is available to residents of Spain through the online consultation. A prescription follows only if the doctor approves it.
- Country
- Spain
- Language of service
- Spanish and English
- Prescription turnaround
- In less than 4 hours on average, only if the doctor approves
- Honoured locally
- QR electronic prescription, dispensed directly in Spain
How the EU prescription works where you are: In Spain, an approved prescription arrives electronically with a QR code for direct dispensing.
VERIFIED EVIDENCE
Caverject: evidence and regulatory guide.
WHAT IT IS
How it works
Alprostadil is a man-made copy of a natural body chemical (prostaglandin E1) that is applied to or injected into the penis, where it widens the blood vessels directly so blood flows in.
DEVELOPMENT STAGE
EU-authorised medicine
Trial register4 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| Integrated analysis of two multicentre, double-blind, parallel-group topical-cream studies | Men with an IIEF erectile function domain score of 25 or less, including men with diabetes and men taking organic nitrates | 1,732 | Read out | 2006-08-01 |
| Alprostadil Study Group — intracavernosal dose-response study | Men with erectile dysfunction of vasculogenic, neurogenic, psychogenic and mixed causes | 296 | Read out | 1996-04-04 |
| Alprostadil Study Group — six-month intracavernosal self-injection study | Men with erectile dysfunction of mixed causes | 683 | Read out | 1996-04-04 |
| MUSE Study Group — transurethral alprostadil, double-blind placebo-controlled trial | Men aged 27-88 with chronic erectile dysfunction from various organic causes | 1,511 | Read out | 1997-01-02 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68(2):386-391. doi:10.1016/j.urology.2006.02.027 (PMID 16904458)| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| 100 microgram cream (n=434) | IIEF erectile function domain change from baseline +1.6 points vs -0.7 on placebo (p<0.001) | 12 |
| 200 microgram cream (n=430) | IIEF erectile function domain change from baseline +2.5 points vs -0.7 on placebo (p<0.001) | 12 |
| 300 microgram cream (n=434) | IIEF erectile function domain change from baseline +2.4 points vs -0.7 on placebo (p<0.001) | 12 |
The IIEF changes are small in absolute terms and the authors describe the SEP2 and SEP3 improvements as slight though statistically significant; the studies ran for 12 weeks and cover the topical cream only, not the injected or intraurethral forms.
Sources
Last reviewed 2026-07-27
- AEMPS CIMA — Caverject 20 microgramos (alprostadil, intracavernosal injection), reg. 60535, first authorised in Spain 29 November 1994, indicated for erectile dysfunction
- AEMPS CIMA — Virirec 3 mg/g crema (alprostadil topical), reg. 78357, first authorised April 2014; the same cream was approved via the EU decentralised procedure as Vitaros in 2013
- Urology 2006 — Integrated analysis of alprostadil topical cream in 1,732 patients (PMID 16904458)
- N Engl J Med 1996 — Efficacy and safety of intracavernosal alprostadil (PMID 8596569)
- N Engl J Med 1997 — Treatment of men with erectile dysfunction with transurethral alprostadil, MUSE Study Group (PMID 8970933)
NAMED SAFETY SIGNALS
What has been reported with Caverject.
Application-site burning, penile pain and redness (cream)
Penile burning, penile pain, penile erythema, genital pain and genital discomfort are all listed as common in the EU product information for alprostadil 3 mg/g cream. In the clinical trial the withdrawal rate was 30% in the 300 microgram group compared with 20% in the 200 microgram group.
Injection-site pain (intracavernosal)
Penile pain is listed as very common in the EU product information for alprostadil injection. In the six-month self-injection study, usually mild penile pain occurred in 50% of men at some time but after only 11% of injections.
Prolonged erection and priapism (intracavernosal)
In the EU product information for alprostadil injection, a prolonged erection lasting 4 to 6 hours developed in 4% of patients and priapism (a painful erection lasting more than 6 hours) in 0.4%. In the six-month self-injection study, prolonged erections occurred in 5% of men and priapism in 1%.
Prolonged erection and priapism (cream)
Listed as uncommon in the EU product information for alprostadil cream. Priapism was seen in 1 patient (0.06%) across the two 3-month studies and in 5 patients (0.4%) in the study lasting more than 6 months. An erection lasting more than 4 hours needs immediate medical help, because untreated priapism can permanently damage erectile tissue.
Penile fibrosis (intracavernosal)
Penile fibrosis, including angulation, fibrotic nodules and Peyronie's disease, was reported in 3% of clinical-trial patients in the EU product information for alprostadil injection, rising to about 8% in a self-administration study of up to 18 months. Injection-site haematoma was reported by 3% and bruising by 2%.
Dizziness and fainting
In the phase 3 cream studies, symptomatic low blood pressure (dizziness) and fainting occurred in 0.4%, 0.4% and 0.5% of patients on the 100, 200 and 300 microgram doses. Patients are advised not to drive or do hazardous tasks until they know how they react.
Effects on a female partner
Vulvovaginal burning and vaginitis are listed as common reactions in female partners in the EU product information for alprostadil cream.
Penile pain (intraurethral)
In the transurethral pivotal trial, mild penile pain was the most common side effect, occurring after 10.8% of treatments; in-clinic low blood pressure occurred in 3.3% of men, and no man had priapism or penile fibrosis.
FormUrethral cream or injection
FrequencyOn demand
ResultsDirect local action
StatusPrescription only
About
What is Caverject?
Active ingredient: Alprostadil · Dosages: Cream 3 mg/g on demand
Alprostadil is a prostaglandin E1 that directly dilates the blood vessels of the penis. It's considered when oral PDE5 inhibitors are ineffective or contraindicated.
It's administered as a urethral cream or an intracavernous injection, under medical instruction — each route has its own efficacy and tolerability profile. Correct technique matters, and the doctor explains the protocol and the warning signs.
How it works in the body
Rather than blocking an enzyme, alprostadil acts directly on the penile blood vessels, dilating them locally — no PDE5 pathway involved, so it can work where oral options don't.
How it helps
How it helps.
A different pathway
Works directly on the blood vessels — not through the PDE5 enzyme.
Local application
Applied where it acts, shortly before intercourse.
Guided by your doctor
Administration technique and warning signs are explained before you start.
What to expect
How to use it.
Prescribed with clear administration instructions. Your doctor explains the protocol, and follow-up happens through your account chat.
- Prescribed with clear administration instructions
- Applied shortly before intercourse
- Correct technique matters — your doctor explains it
- Follow-up and questions through your account chat
Forms your doctor can prescribe
- Urethral cream3 mg/g — on demand
Your schedule is personal
These are typical steps only. Your doctor adjusts the plan to how you respond and tolerate it — and you can message them at any point.
Safety first
Safety, in full.
Caverject is an effective medicine — and like any medicine it carries risks. Your doctor screens for all of this before prescribing. Here's the honest picture, not just reassurance.
Erectile dysfunction in adult men, as a local alternative to tablets.
- Apply the single-use dose to the opening at the tip of the penis 5–30 minutes before sex, following the leaflet's technique.
- The effect lasts around 1–2 hours.
- Maximum one dose per 24 hours, and no more than 2–3 doses per week.
- Wash hands after applying.
Who should not take it
- Conditions that predispose to prolonged erections — sickle cell disease or trait, leukaemia, multiple myeloma.
- An abnormally shaped penis, a penile implant, or severe scarring (Peyronie's disease) — discuss with the doctor first.
- Men for whom sexual activity is inadvisable, for example because of severe heart disease.
- Allergy to alprostadil or any ingredient of the cream.
- If your partner is pregnant or breastfeeding, use a condom during sex.
When to seek urgent care
For severe, sudden or unexpected symptoms, call your local emergency number or go to the nearest emergency department. Then let your doctor know through your account chat.
PRICING
You only pay if treatment is approved.
€35 for one sexual-health consultation. Paid once, with no recurring charge.
Sexual health
ONE-OFF
€35 one-off
One consultation, one doctor, one decision.
Nothing stored publicly, ever
Start consultation
Full refund if a review is not approved
WHAT'S INCLUDED
- Consultation reviewed by an EU-licensed doctor
- Electronic prescription if approved
- Full refund if not approved
Full refund if a review is not approved
If a review is not approved, we refund the €35 consultation fee in full.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
HOW THE DOCTOR DECIDES
A licensed doctor reviews your case, not an algorithm
An EU-licensed doctor reads your questionnaire and answers in less than 2 hours on average.
If the doctor decides it is not safe to prescribe, the consultation fee is refunded in full.
Follow-up happens in the private chat inside your account, under GDPR. No WhatsApp, no SMS.
OTHER SEXUAL HEALTH TREATMENTS
Explore related treatments.
Find out if it's right for you
See if Caverject is appropriate for you.
Answer a few questions and a licensed EU doctor reviews your case in less than 2 hours on average. Refunded in full if it's not right for you.